In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 8, 1996, Pages 683-685

  Verbist, L ^a   Verhaegen, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0029842395     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691160     Document Type: Article

References (3)

1. Gooding BB, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 1993, 37: 349-353.
2. Eliopoulos GM, Klimm K, Eliopoulos T, Ferraro MJ, Moellering RC: In vitro activity of CP 99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1993, 37: 366-370.
3. Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP 99,219 compared to those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 1994, 38: 2471-2476.